Figure 5. Depletion of Peripheral Blood CD21+ and CD21- B-cell subsets.

Short and long-term analysis of PBMC B-cell depletion of (A) CD21+ and (B) CD21- B-cell subsets (as identified in Figure 2C). Individuals animal samples with mean shown for baseline, day 2, day 9 and day 14 post second dose (top) and percent remaining as normalized to PBS vehicle treated group (bottom) (group mean ± SD (n=4 rituximab treated groups, n=3 PBS vehicle treated groups).